英文标题:Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations 中文标题:阿美替尼辅助治疗伴罕见EGFR突变的完全切除的IA2-IIIA期NSCLC 讲者:H. Ye(...
[1]Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. [2]Lynch TJ, Bell DW, Sordella R, et al. A...
参考文献：[1]Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220-9.[2]Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular ch...
[1] Gou L Y, Wu Y L. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China[J]. Lung Cancer, 2014, 5(default):1-9. [2] Ramalingam S S , Vansteenkiste J , Planchard D , et al. Overall Survival with Osimertinib in Untreated, EGFR -Mut...
[3]Kobayashi Y,Mitsudomi T.Not all epidermal growth factor receptor mutations in lung cancer are created equal:Perspectives for individualized treatment strategy.Cancer Sci.2016;107(9):1179-86.doi:10.1111/cas.12996. [4]Robichaux JP,Elamin YY,Tan Z,et al.Mechanisms and clinical activity of an...
1. Li, F. et al. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.J. Immunother. Cancer9, e002531 (2021). 2. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of ...
Non-small-cell lung cancerTumour heterogeneitymutations account for the majority of druggable targets in lung adenocarcinoma. Over the past decades the optimization of EGFR inhibitors revolutionized the treatment options for patients suffering from this disease. The pace of this development was largely ...
Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients Lung cancer is the leading global cause of cancer-related mortality. Inter-individual variability in treatment response and prognosis has been associated w... JG Carneiro,PG Couto,L Bastos...
Treatment of Non-small Cell Lung Cancer with EGFR-mutations. J UOEH. 2019;41(2):153-163. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research....
[3]Kobayashi Y,Mitsudomi T.Not all epidermal growth factor receptor mutations in lung cancer are created equal:Perspectives for individualized treatment strategy.Cancer Sci.2016;107(9):1179-86.doi:10.1111/cas.12996. [4]Robichaux JP,Elamin YY,Tan Z,et al.Mechanisms and clinical activity of an...